Jazz Pharmaceuticals JAZZ Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's effective income tax rate reconciliation equity in earnings losses of unconsolidated subsidiary.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's effective income tax rate reconciliation equity in earnings losses of unconsolidated subsidiary?
- Jazz Pharmaceuticals (JAZZ) reported effective income tax rate reconciliation equity in earnings losses of unconsolidated subsidiary of -14.5% in Q4 2025.
- What does effective income tax rate reconciliation equity in earnings losses of unconsolidated subsidiary mean?
- The effect of income or losses from partial ownership stakes on the overall tax rate.
- How do you interpret effective income tax rate reconciliation equity in earnings losses of unconsolidated subsidiary?
- Changes reflect the tax-adjusted performance of equity-method investments.
- How does effective income tax rate reconciliation equity in earnings losses of unconsolidated subsidiary compare across companies?
- Standard tax reconciliation item for companies with complex corporate structures and strategic partnerships.